GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

I'm Interested!

Please call
1-800-641-2422

Phase 1 Trial With GD2-SADA:177Lu-DOTA Drug Complex in Patients With Recurrent or Refractory Metastatic Solid Tumors Known to Express GD2, Including Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma

Sex at Birth: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Solid Tumor

Study Purpose

Patients with Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA) to assess safety and tolerability

Principal Investigator
Afshin Dowlati MD

Department/Division
Cancer (Any Solid Tumor)

Locations

UH Seidman Cancer Center
11100 Euclid Avenue
Cleveland OH, 44106

Get Directions

UH IRB: STUDY20221537
StudyID: YMAB1Y22
ClinicalTrials.gov: NCT05130255

I'm Interested!

Please call
1-800-641-2422

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422